Allergy Delabeling in Antibiotic Stewardship - Evaluations

Last updated: June 4, 2026
Sponsor: Abramson Cancer Center at Penn Medicine
Overall Status: Active - Enrolling

Phase

N/A

Condition

Neoplasms

Allergy

Allergies & Asthma

Treatment

Semi-structured interview

Ethnographic observation

Survey

Clinical Study ID

NCT06967467
02725
R01HS029879
  • Ages > 18
  • All Genders

Study Summary

The goal of this RENEW-EVAL project is to understand the potential barriers to implementation of the RENEW intervention into the routine clinical care of patients with a hematological malignancy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patient participants:

  • a diagnosis of a hematologic malignancy (lymphoma, leukemia, myeloma)

  • a prior label applied to their medical record to indicate a beta lactam allergy

  • hospitalized as an inpatient to an oncology service at the time the study isconducted

Clinician participants:

  • member of the primary inpatient care team

Exclusion

Exclusion Criteria:

Patient participants:

  • meet one of the exclusionary criteria for the RENEW clinical intervention

Clinician participants:

  • no exclusions

Study Design

Total Participants: 80
Treatment Group(s): 3
Primary Treatment: Semi-structured interview
Phase:
Study Start date:
December 01, 2025
Estimated Completion Date:
October 31, 2029

Study Description

The RENEW clinical intervention is designed to evaluate the impact of a comprehensive beta lactam (BL) allergy delabeling intervention on clinical outcomes among patients hospitalized with a hematologic malignancy (HM). HM patients are at a high risk of infection-related complications but are limited to antibiotic therapy based on self-reported allergies. The RENEW intervention will test the impact of a pharmacist-led BL allergy delabeling intervention on clinical outcomes and antibiotic use in hospitalized patients with HM.

The implementation of clinical interventions are often affected by non-clinical factors including workflow challenges and the beliefs of patients, their families, and clinical staff.

The RENEW-EVAL study is a concurrent mixed methods process evaluation of the RENEW intervention that aims to identify the social and behavioral factors that shape implementation of the intervention and to measure implementation outcomes including feasibility, acceptability, and fidelity.

Three types of data will be gathered by the research team as part of the RENEW-EVAL project: 1) semistructured interviews with patients and clinicians, (2) ethnographic observations of the delivery of the RENEW intervention, and 3) surveys assessing patient and clinician attitudes towards BL allergy delabeling, and implementation outcomes.

Connect with a study center

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.